Children and adolescents with ASD often have problems talking with other people and making friends. They usually also have repetitive behaviours that interfere with their day-to-day living.
The POND Network Clinical Trials Group is looking for young people with ASD, aged 12 to 17, to take part in a study of the medication tideglusib. The goal of the study is to see if the medication tideglusib helps to improve symptoms of Autism Spectrum Disorder, specifically social engagement, social function (e.g., learning how to talk to others, making friends) and repetitive behaviours.
The study lasts a total of 16 weeks (about 4 months) and involves taking the medication dissolved in water every day for three months, with a follow up visit one month later. You and your child will first be asked to come in for a screening session; through talking with you and completing some assessments we will determine if your child meets eligibility criteria. If your child meets criteria, then you will then receive either tideglusib or placebo. Visits will take place every two weeks while your child is taking the drug or placebo. This study also has an optional continuation part, which means that if you were given placebo, you will be able to take tideglusib at the end of the four months. The same tests and procedures will be followed that were followed during the main study.
For more information about this study, please contact one of the participating sites below:
Holland Bloorview Kids Rehabilitation Hospital, Toronto, ON
Naomi Peleg, Tideglusib Study Coordinator
npeleg@hollandbloorview.ca
(416) 425.6220 x 3456
Western University / Lawson Health Research Institute, London, ON
Ahsan Ahmad, Tideglusib Study Coordinator
Ahsan.Ahmad@lhsc.on.ca
(519) 685-8500 x 74906
McMaster University, Hamilton, ON
Alessia Greco, Tideglusib Study Coordinator
algreco@mcmaster.ca
(905) 521-2100 x 74906
The doctors involved in this study at each of POND’s research sites are:
Dr. Evdokia Anagnostou, Holland Bloorview Kids Rehabilitation Hospital
Dr. Rob Nicholson, Lawson Health Research Institute
Dr. Teresa Bennett, McMaster University/McMaster Children’s Hospital